Anticoagulation with rivaroxaban in a hematology unit: clinical profile, events and discontinuation rates in real-life patients with nonvalvular atrial fibrillation

Future Cardiol. 2018 May;14(3s):25-30. doi: 10.2217/fca-2018-0023.

Abstract

Aim: To assess the clinical profile and thromboembolic and bleeding events in patients with nonvalvular atrial fibrillation (AF) who were attended in a hematology unit.

Methods: Retrospective study of AF patients that started treatment with rivaroxaban between February 2012 and June 2016 in a hematology unit from a tertiary hospital in Spain.

Results: Overall, 243 patients (mean age 78.4 ± 10.1 years; 47.5% women, CHA2DS2-VASc 3.7 ± 1.5) were included. After a mean follow-up of 16.5 ± 12.7 months, rivaroxaban was discontinued in only 2.4% of patients. During the follow-up, seven (2.0 events/100 patient-years) patients had a thromboembolic event and six patients (1.7 events/100 patient-years) a major bleeding.

Conclusion: Rivaroxaban was effective and safe among AF patients treated in a hematology unit, with very low discontinuation rates.

Keywords: anticoagulation clinic; atrial fibrillation; clinical practice; effectiveness; hematology unit; rivaroxaban; safety.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Factor Xa Inhibitors / therapeutic use*
  • Female
  • Hemorrhage / epidemiology*
  • Hospital Units
  • Humans
  • Male
  • Practice Patterns, Physicians'
  • Retrospective Studies
  • Rivaroxaban / therapeutic use*
  • Spain
  • Stroke / etiology
  • Stroke / prevention & control*
  • Tertiary Care Centers
  • Thromboembolism / epidemiology*

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban